Identification

Name
Paliperidone
Accession Number
DB01267
Type
Small Molecule
Groups
Approved
Description

Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.

Structure
Thumb
Synonyms
  • 9-Hydroxyrisperidone
  • Paliperidone
  • Ro-76477
Product Ingredients
IngredientUNIICASInChI Key
Paliperidone palmitateR8P8USM8FR199739-10-1VOMKSBFLAZZBOW-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release12 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release1.5 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release3 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release6 mgOralJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaTablet, extended release9 mg/1OralJanssen Pharmaceuticals2006-12-19Not applicableUs50458 0552 01 nlmimage10 0e160770
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PaliperidoneTablet, film coated, extended release3 mg/1OralActavis Pharma Company2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release3 mg/1OralMylan Institutional2016-09-20Not applicableUs
PaliperidoneTablet, film coated, extended release1.5 mg/1OralMylan Pharmaceuticals2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release9 mg/1OralMylan Pharmaceuticals2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release6 mg/1OralMylan Institutional2016-09-15Not applicableUs
PaliperidoneTablet, film coated, extended release6 mg/1OralActavis Pharma Company2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release3 mg/1OralMylan Pharmaceuticals2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release1.5 mg/1OralActavis Pharma Company2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release6 mg/1OralCarilion Materials Management2015-09-24Not applicableUs
PaliperidoneTablet, film coated, extended release9 mg/1OralActavis Pharma Company2015-09-24Not applicableUs
International/Other Brands
Invega
Categories
UNII
838F01T721
CAS number
144598-75-4
Weight
Average: 426.4839
Monoisotopic: 426.206718955
Chemical Formula
C23H27FN4O3
InChI Key
PMXMIIMHBWHSKN-UHFFFAOYSA-N
InChI
InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
IUPAC Name
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
SMILES
CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1

Pharmacology

Indication

For the treatment of schizophrenia.

Structured Indications
Pharmacodynamics

Paliperidone is an atypical antipsychotic developed by Janssen Pharmaceutica. Chemically, paliperidone is primary active metabolite of the older antipsychotic risperidone (paliperidone is 9-hydroxyrisperidone). While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not the same, pathways.

Mechanism of action

Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(2) dopamine receptor
antagonist
Human
UHistamine H1 receptor
agonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
AD(4) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 1D
antagonist
Human
AD(3) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2C
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
agonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UCytochrome P450 3A4Not AvailableHuman
UCytochrome P450 2D6Not AvailableHuman
UCytochrome P450 3A5Not AvailableHuman
U5-hydroxytryptamine receptor 7Not AvailableHuman
Absorption

The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.

Volume of distribution
  • 487 L
Protein binding

The plasma protein binding of racemic paliperidone is 74%.

Metabolism

Although in vitro studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, in vivo results indicate that these isozymes play a limited role in the overall elimination of paliperidone. Four primary metabolic pathways have been identified in vivo, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission. Paliperidone does not undergo extensive metabolism and a significant portion of its metabolism occurs in the kidneys.

Route of elimination

One week following administration of a single oral dose of 1 mg immediate-release 14C-paliperidone to 5 healthy volunteers, 59% (range 51% – 67%) of the dose was excreted unchanged into urine, 32% (26% – 41%) of the dose was recovered as metabolites, and 6% – 12% of the dose was not recovered.

Half life

The terminal elimination half-life of paliperidone is approximately 23 hours.

Clearance
Not Available
Toxicity

The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Paliperidone.Investigational
2,5-Dimethoxy-4-ethylamphetaminePaliperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePaliperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePaliperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with 7-Nitroindazole.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Paliperidone.Approved, Investigational
AcebutololPaliperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Paliperidone.Investigational, Withdrawn
AdipiplonThe risk or severity of adverse effects can be increased when Paliperidone is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Paliperidone.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Paliperidone.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Paliperidone.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Paliperidone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paliperidone.Approved, Illicit, Investigational
AlprenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Paliperidone.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Paliperidone.Illicit, Withdrawn
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Paliperidone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Paliperidone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amperozide.Experimental
AmphetaminePaliperidone may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideAnagrelide may increase the QTc-prolonging activities of Paliperidone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ArotinololPaliperidone may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ArtemetherPaliperidone may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
AtenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Paliperidone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Azaperone.Investigational, Vet Approved
AzelastinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Paliperidone.Approved
BaclofenThe risk or severity of adverse effects can be increased when Paliperidone is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Paliperidone.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Barbital.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Paliperidone.Approved
BefunololPaliperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Paliperidone.Investigational
BenperidolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Benzocaine.Approved
BenzphetaminePaliperidone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Paliperidone is combined with Benzyl alcohol.Approved
BetaxololPaliperidone may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BisoprololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Paliperidone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Paliperidone.Investigational, Withdrawn
BufuralolPaliperidone may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Bupivacaine.Approved, Investigational
BupranololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Paliperidone.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Paliperidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paliperidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Paliperidone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paliperidone.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.Approved
CanertinibThe risk or severity of adverse effects can be increased when Paliperidone is combined with Canertinib.Investigational
CarbamazepineThe serum concentration of Paliperidone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carbinoxamine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Paliperidone.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carisoprodol.Approved
CarteololPaliperidone may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolPaliperidone may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Paliperidone.Experimental
CeliprololPaliperidone may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibCeritinib may increase the QTc-prolonging activities of Paliperidone.Approved
CetirizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paliperidone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorphenamine.Approved
ChlorphenterminePaliperidone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Paliperidone.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorzoxazone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Paliperidone.Experimental
CinchocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Paliperidone.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Paliperidone.Approved
ClemastineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with clomethiazole.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Paliperidone.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clopenthixol.Experimental
CloranololPaliperidone may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paliperidone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Paliperidone.Approved
CocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Paliperidone.Approved, Illicit
CrizotinibCrizotinib may increase the QTc-prolonging activities of Paliperidone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Paliperidone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyproheptadine.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Paliperidone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dapoxetine.Investigational
DasatinibDasatinib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Paliperidone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Paliperidone.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Paliperidone.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Paliperidone.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Paliperidone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetaminePaliperidone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Paliperidone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Paliperidone.Approved, Illicit, Vet Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Paliperidone.Experimental
Diethyl etherThe risk or severity of adverse effects can be increased when Paliperidone is combined with Diethyl ether.Experimental
DiethylpropionPaliperidone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paliperidone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Paliperidone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paliperidone.Approved, Illicit
DisopyramideDisopyramide may increase the QTc-prolonging activities of Paliperidone.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dixyrazine.Experimental
DofetilideDofetilide may increase the QTc-prolonging activities of Paliperidone.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Paliperidone.Approved
DomperidoneDomperidone may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Doramectin.Vet Approved
DosulepinDosulepin may decrease the antihypertensive activities of Paliperidone.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Paliperidone.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Paliperidone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Illicit
DronedaronePaliperidone may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Paliperidone.Approved
DuloxetineDuloxetine may decrease the antihypertensive activities of Paliperidone.Approved
DyclonineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Paliperidone is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Paliperidone.Approved, Investigational
EliglustatPaliperidone may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Eltanolone.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Entacapone.Approved, Investigational
EpanololPaliperidone may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paliperidone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paliperidone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Paliperidone.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Paliperidone.Investigational
EsmololPaliperidone may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Paliperidone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paliperidone.Approved
EthanolPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etorphine.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Paliperidone.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Paliperidone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Paliperidone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Paliperidone.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fexofenadine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Paliperidone.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluanisone.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Paliperidone.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Paliperidone.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Paliperidone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paliperidone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paliperidone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Paliperidone.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Paliperidone.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paliperidone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Paliperidone is combined with Gabapentin Enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Paliperidone.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Paliperidone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Paliperidone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
GepefrinePaliperidone may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Paliperidone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Paliperidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Paliperidone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Paliperidone.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Paliperidone.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Paliperidone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Paliperidone.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Paliperidone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Paliperidone.Approved
HydrocodonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone.Approved, Illicit
HydroxyamphetaminePaliperidone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Paliperidone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Iloperidone.Approved
ImipramineImipramine may decrease the antihypertensive activities of Paliperidone.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Paliperidone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Paliperidone.Approved
IndenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Paliperidone is combined with Indiplon.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Paliperidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Paliperidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Paliperidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Paliperidone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Paliperidone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Paliperidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Paliperidone.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Paliperidone.Approved, Investigational
Iofetamine I-123Paliperidone may decrease the stimulatory activities of Iofetamine I-123.Approved
IprindoleIprindole may decrease the antihypertensive activities of Paliperidone.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paliperidone.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Paliperidone.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Paliperidone.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Paliperidone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketobemidone.Approved, Investigational
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
LabetalolPaliperidone may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lamotrigine.Approved, Investigational
LandiololPaliperidone may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Paliperidone.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Paliperidone.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Paliperidone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Paliperidone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Paliperidone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Paliperidone.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Paliperidone.Approved
LisdexamfetaminePaliperidone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Paliperidone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lofentanil.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Paliperidone.Experimental
LopinavirPaliperidone may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paliperidone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Paliperidone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Paliperidone.Approved
LumefantrinePaliperidone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Vet Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Paliperidone.Approved
MebicarThe risk or severity of adverse effects can be increased when Paliperidone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Paliperidone.Approved
MelatoninThe risk or severity of adverse effects can be increased when Paliperidone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Melperone.Approved, Investigational
MephedronePaliperidone may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePaliperidone may decrease the stimulatory activities of Mephentermine.Approved
MepindololPaliperidone may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Meptazinol.Experimental
MequitazinePaliperidone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Paliperidone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methadyl Acetate.Approved, Illicit
MethamphetaminePaliperidone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Paliperidone.Approved
MethotrimeprazinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenaminePaliperidone may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.Approved, Investigational
MetoprololPaliperidone may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Paliperidone.Approved
MetyrosinePaliperidone may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone.Approved, Illicit
MidomafetaminePaliperidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Paliperidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Paliperidone.Approved
MilnacipranMilnacipran may decrease the antihypertensive activities of Paliperidone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Paliperidone.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Paliperidone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Paliperidone.Approved, Investigational
MMDAPaliperidone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Paliperidone.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Paliperidone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Paliperidone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved, Investigational
NadololPaliperidone may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Paliperidone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Paliperidone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Paliperidone.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Paliperidone.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Paliperidone.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Paliperidone.Approved
NilotinibPaliperidone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nitrous oxide.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Paliperidone.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Paliperidone.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Paliperidone.Investigational
OpiumThe risk or severity of adverse effects can be increased when Paliperidone is combined with Opium.Approved, Illicit
OrphenadrinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Paliperidone is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paliperidone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Oxethazaine.Approved, Investigational
OxprenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Paliperidone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Paliperidone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
ParaldehydePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Paliperidone.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Paliperidone.Approved
PenbutololPaliperidone may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Penfluridol.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Paliperidone.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paliperidone.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Paliperidone.Approved
PerospironeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paliperidone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Paliperidone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Paliperidone.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paliperidone.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenoxyethanol.Approved
PhenterminePaliperidone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Paliperidone.Approved
PindololPaliperidone may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Paliperidone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Paliperidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pomalidomide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational, Vet Approved
PractololPaliperidone may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexolePaliperidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Paliperidone.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paliperidone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Prilocaine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Paliperidone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Primidone.Approved, Vet Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Paliperidone.Approved
ProcaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paliperidone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Paliperidone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Paliperidone.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Paliperidone.Approved
PropanididThe risk or severity of adverse effects can be increased when Paliperidone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Propoxycaine.Approved
PropranololPaliperidone may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Paliperidone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Paliperidone is combined with PSD502.Investigational
PseudoephedrinePaliperidone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Paliperidone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Paliperidone.Approved
QuinidineQuinidine may increase the QTc-prolonging activities of Paliperidone.Approved
QuinineQuinine may increase the QTc-prolonging activities of Paliperidone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ramelteon.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Paliperidone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Paliperidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Paliperidone.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Paliperidone.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Paliperidone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ritanserin.Investigational
RitobegronPaliperidone may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Paliperidone.Approved
RomifidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Romifidine.Vet Approved
RopinirolePaliperidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Paliperidone.Approved, Investigational
RotigotinePaliperidone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Paliperidone.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Paliperidone.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Paliperidone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paliperidone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Paliperidone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Paliperidone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Paliperidone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Paliperidone.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Paliperidone.Investigational
SotalolPaliperidone may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
St. John's WortThe serum concentration of Paliperidone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Paliperidone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Paliperidone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Paliperidone.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
SuvorexantPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TalinololPaliperidone may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Paliperidone.Approved
TandospironeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Paliperidone.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Paliperidone.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Paliperidone.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Paliperidone.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Paliperidone.Approved
TertatololPaliperidone may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Paliperidone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrodotoxin.Investigational
ThalidomidePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Paliperidone.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Paliperidone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Paliperidone.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tilidine.Experimental
TimololPaliperidone may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Paliperidone.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Paliperidone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Paliperidone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Topiramate.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Paliperidone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Paliperidone.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paliperidone.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Paliperidone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Paliperidone.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Paliperidone.Investigational, Withdrawn
Valproic AcidThe serum concentration of Paliperidone can be increased when it is combined with Valproic Acid.Approved, Investigational
VandetanibPaliperidone may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Paliperidone.Approved
VemurafenibPaliperidone may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Paliperidone.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Paliperidone.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Paliperidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Paliperidone.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Paliperidone.Approved, Investigational
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Paliperidone.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Paliperidone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paliperidone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Paliperidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paliperidone.Approved, Investigational
ZolpidemPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Paliperidone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.

References

Synthesis Reference

Santiago Ini, Naama Chasid, Kobi Chen, Osnat Porter-Kleks, "Pure paliperidone and processes for preparing thereof." U.S. Patent US20080171876, issued July 17, 2008.

US20080171876
General References
  1. Jones MP, Nicholl D, Trakas K: Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther. 2010 Jun;48(6):383-99. [PubMed:20497747]
  2. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577]
External Links
Human Metabolome Database
HMDB15396
KEGG Drug
D05339
PubChem Compound
115237
PubChem Substance
46506296
ChemSpider
103109
BindingDB
50252513
ChEBI
83804
ChEMBL
CHEMBL1621
Therapeutic Targets Database
DAP000847
PharmGKB
PA163518919
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Paliperidone
ATC Codes
N05AX13 — Paliperidone
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableEpilepsies / Schizophrenic Disorders1
1CompletedBasic ScienceBipolar Disorder (BD) / Depressive Disorders / Psychotic Disorder NOS / Schizophrenic Disorders1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders2
1CompletedTreatmentSchizophrenic Disorders8
1RecruitingNot AvailableAntipsychotics / Immunoassay1
2CompletedTreatmentChronic Schizophrenia / Schizoaffective Disorders1
2CompletedTreatmentObsessive-Compulsive Disorder (OCD)1
2CompletedTreatmentSchizophrenic Disorders2
2CompletedTreatmentSchizophrenic Disorders / Sleeplessness1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
3Active Not RecruitingTreatmentAmphetamine Dependence / Heroin Dependence1
3Active Not RecruitingTreatmentSchizophrenic Disorders1
3CompletedPreventionSchizoaffective Disorders1
3CompletedPreventionSchizophrenic Disorders1
3CompletedTreatmentAffective Psychosis, Bipolar / Bipolar Disorder (BD) / Mania1
3CompletedTreatmentAutism, Early Infantile1
3CompletedTreatmentBipolar Disorder (BD)1
3CompletedTreatmentBipolar Disorder (BD) / Moods Disorders1
3CompletedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders2
3CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentSchizophrenic Disorders29
3RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedNot AvailableSchizophrenic Disorders3
4CompletedPreventionSchizophrenic Disorders1
4CompletedTreatmentAcute Disease / Psychomotor Agitation1
4CompletedTreatmentFirst Episode Psychosis1
4CompletedTreatmentMajor Depressive Disorder (MDD) / Suicidal Ideation1
4CompletedTreatmentMethamphetamine Dependence1
4CompletedTreatmentPsychotic Disorder NOS1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders3
4CompletedTreatmentSchizophrenic Disorders20
4Not Yet RecruitingTreatmentSchizophrenic Disorders2
4RecruitingTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4RecruitingTreatmentSchizophrenia (Recent-onset)1
4RecruitingTreatmentSchizophrenic Disorders2
4TerminatedNot AvailableSchizophrenic Disorders1
4TerminatedPreventionSchizophrenic Disorders1
4TerminatedTreatmentPediatric Bipolar Disorder1
4TerminatedTreatmentSchizophrenic Disorders2
4Unknown StatusTreatmentSchizophrenic Disorders1
4WithdrawnPreventionSchizophrenic Disorders1
4WithdrawnTreatmentBipolar Disorder (BD)1
4WithdrawnTreatmentPosttraumatic Stress Disorders1
Not AvailableActive Not RecruitingNot AvailableSchizophrenic Disorders1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentMethamphetamine Dependence1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableRecruitingTreatmentSchizophrenic Disorders1
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders / Schizophreniform1
Not AvailableWithdrawnTreatmentSchizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral1.5 mg
Tablet, extended releaseOral12 mg
Tablet, extended releaseOral3 mg/1
Tablet, extended releaseOral3 mg
Tablet, extended releaseOral6 mg/1
Tablet, extended releaseOral6 mg
Tablet, extended releaseOral9 mg/1
Tablet, extended releaseOral9 mg
InjectionIntramuscular117 mg/.75mL
InjectionIntramuscular156 mg/mL
InjectionIntramuscular234 mg/1.5mL
InjectionIntramuscular39 mg/.25mL
InjectionIntramuscular78 mg/.5mL
Suspension, extended releaseIntramuscular100 mg
Suspension, extended releaseIntramuscular150 mg
Suspension, extended releaseIntramuscular25 mg
Suspension, extended releaseIntramuscular50 mg
Suspension, extended releaseIntramuscular75 mg
Injection, suspension, extended releaseIntramuscular273 mg/.875mL
Injection, suspension, extended releaseIntramuscular410 mg/1.315mL
Injection, suspension, extended releaseIntramuscular546 mg/1.75mL
Injection, suspension, extended releaseIntramuscular819 mg/2.625mL
Suspension, extended releaseIntramuscular175 mg
Suspension, extended releaseIntramuscular263 mg
Suspension, extended releaseIntramuscular350 mg
Suspension, extended releaseIntramuscular525 mg
Tablet, extended releaseOral1.5 mg/1
Tablet, film coated, extended releaseOral1.5 mg/1
Tablet, film coated, extended releaseOral3 mg/1
Tablet, film coated, extended releaseOral6 mg/1
Tablet, film coated, extended releaseOral9 mg/1
Injection, suspension, extended releaseIntramuscular100 mg
Injection, suspension, extended releaseIntramuscular150 mg
Injection, suspension, extended releaseIntramuscular25 mg
Injection, suspension, extended releaseIntramuscular50 mg
Injection, suspension, extended releaseIntramuscular75 mg
Prices
Unit descriptionCostUnit
Invega sustenna 39 mg pref syringe296.45USD syringe
Invega er 6 mg tablet28.62USD tablet
Invega er 9 mg tablet23.59USD tablet
Invega er 3 mg tablet23.09USD tablet
Invega er 1.5 mg tablet15.72USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5254556No1993-10-272010-10-27Us
CA2494234No2009-10-272023-07-28Canada
CA2000786No1999-01-262009-10-16Canada
US6077843Yes1997-11-122017-11-12Us
US6555544Yes1999-05-102019-05-10Us
US9439906No2011-01-262031-01-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityPractically insoluble in waterNot Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.297 mg/mLALOGPS
logP2.3ALOGPS
logP1.76ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)13.74ChemAxon
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area82.17 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.04 m3·mol-1ChemAxon
Polarizability45.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7928
Caco-2 permeable-0.5496
P-glycoprotein substrateSubstrate0.7449
P-glycoprotein inhibitor IInhibitor0.7011
P-glycoprotein inhibitor IIInhibitor0.8229
Renal organic cation transporterNon-inhibitor0.6231
CYP450 2C9 substrateNon-substrate0.7721
CYP450 2D6 substrateSubstrate0.5131
CYP450 3A4 substrateSubstrate0.7154
CYP450 1A2 substrateNon-inhibitor0.7379
CYP450 2C9 inhibitorNon-inhibitor0.7395
CYP450 2D6 inhibitorNon-inhibitor0.5326
CYP450 2C19 inhibitorNon-inhibitor0.7815
CYP450 3A4 inhibitorNon-inhibitor0.6468
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7558
Ames testNon AMES toxic0.518
CarcinogenicityNon-carcinogens0.7995
BiodegradationNot ready biodegradable0.9908
Rat acute toxicity3.7859 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8366
hERG inhibition (predictor II)Inhibitor0.7061
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0000900000-455daaf1442d16f7bdaa
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0010900000-dfa5205279a00e3db1e5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0090300000-40916890e9a9a7068fa9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0090000000-e69a1027f43e06f96a84
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0090000000-5a71379b6aa632f43ea0

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridopyrimidines. These are compounds containing a pyridopyrimidine, which consists of a pyridine fused to a pyrimidine. Pyridine is 6-membered ring consisting of five carbon atoms and a nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridopyrimidines
Sub Class
Not Available
Direct Parent
Pyridopyrimidines
Alternative Parents
Benzisoxazoles / Aralkylamines / Pyrimidones / Aryl fluorides / Benzenoids / Piperidines / Pyridines and derivatives / Isoxazoles / Heteroaromatic compounds / Lactams
show 8 more
Substituents
Pyridopyrimidine / Benzisoxazole / Pyrimidone / Aralkylamine / Aryl fluoride / Aryl halide / Benzenoid / Piperidine / Pyridine / Pyrimidine
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, secondary alcohol, pyridopyrimidine, 1,2-benzoxazoles, heteroarylpiperidine (CHEBI:83804)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043]
  2. He H, Richardson JS: A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995 Mar;10(1):19-30. [PubMed:7542676]
  3. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
  4. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  6. Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T: Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. Synapse. 2002 Oct;46(1):32-7. [PubMed:12211096]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
  3. Regenthal R, Kunstler U, Hesse S, Sabri O, Preiss R: D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. Int J Clin Pharmacol Ther. 2005 Aug;43(8):370-8. [PubMed:16119512]
  4. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S: A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006 Mar;163(3):396-401. [PubMed:16513859]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  6. Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T: Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. Synapse. 2002 Oct;46(1):32-7. [PubMed:12211096]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
3. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  4. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090]
  5. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
  6. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10. [PubMed:18542932]
  7. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  8. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  4. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090]
  5. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
  6. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10. [PubMed:18542932]
  7. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  8. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Gunes A, Spina E, Dahl ML, Scordo MG: ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008 Oct;30(5):628-33. doi: 10.1097/FTD.0b013e3181858ca9. [PubMed:18708991]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Boerth JM, Caley CF, Goethe JW: Interpreting serum risperidone concentrations. Pharmacotherapy. 2005 Feb;25(2):299-302. [PubMed:15767244]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8. [PubMed:11560868]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Knight JA, Smith C, Toohey N, Klein MT, Teitler M: Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol. 2009 Feb;75(2):374-80. doi: 10.1124/mol.108.052084. Epub 2008 Nov 7. [PubMed:18996971]
  2. Toohey N, Klein MT, Knight J, Smith C, Teitler M: Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other "inactivating antagonists". Mol Pharmacol. 2009 Sep;76(3):552-9. doi: 10.1124/mol.109.056283. Epub 2009 Jun 9. [PubMed:19509219]
  3. Teitler M, Toohey N, Knight JA, Klein MT, Smith C: Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions. Psychopharmacology (Berl). 2010 Dec;212(4):687-97. doi: 10.1007/s00213-010-2001-x. Epub 2010 Sep 9. [PubMed:20827463]

Drug created on May 16, 2007 14:09 / Updated on November 13, 2017 21:49